Neurocrine Biosciences Inc is a biopharmaceutical company dedicated to developing innovative therapies for neurological and endocrine disorders. The company's mission is to improve the lives of patients by addressing unmet medical needs through cutting-edge research and development. Neurocrine Biosciences Inc employs a strategic focus on advancing its pipeline of product candidates, leveraging partnerships, and utilizing its expertise in drug discovery and clinical development. With a commitment to scientific excellence, the company aims to deliver transformative treatments that enhance patient outcomes and quality of life.

NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences, a mid-cap biopharmaceutical company based in San Diego, California, recently held its fourth-quarter earnings conference call on February 6, 2025. The company, known for its focus on neuroscience drug development, has successfully created four FDA-approved drugs, including INGREZZA (valbenazine), which treats tardive dyskinesia (TD).

Neurocrine Biosciences Reports Mixed Q4 Earnings and Faces Analyst Skepticism on Ingrezza Sales Outlook